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Abstract 
 
Purpose: To study the relationship between systemic pro-inflammatory factors and macular 
structural response to intravitreal bevacizumab for diabetic macular edema (DME)  
Methods: Prospective study including 30 cases with DME, treated with bevacizumab and a 
minimum follow-up of 6 months. All cases underwent baseline laboratory testing for 
cardiovascular risk (high sensitivity C-reactive protein (hsCRP), homocystein), dyslipidemia, 
renal dysfunction and glucose control. Serum levels of VEGF, soluble ICAM-1, MCP-1 and TNF-α 
were assessed by enzyme-linked immunosorbent assay kits. Significant associations between 
systemic factors and quantitative and qualitative spectral-domain optical coherence macular 
features were analyzed  
Results: A mean of 4.82±0.56 intravitreal injections was performed, resulting in significant 
improvement of central foveal thickness (CFT) (p<0.001). A significant association with third 
month CFT decrease < 10% was found for hsCRP (3.33±2.01 vs 1.39±1.15 mg/L, p=0.007) and 
ICAM1 (975.54±265.49 vs 727.07±336.09 pg/ml, p=0.012). ROC curve analysis indicated hsCRP 
and ICAM1 as significant biomarkers for 3rd month reduced anatomic response (area under 
the curve (AUC)=0.807, p=0.009 for hsCRP; AUC=0.788, p=0.014 for ICAM1). ROC curve 
analysis revealed hsCRP as a significant biomarker for 6th month CFT decrease < 10% 
(AUC=0.903, p<0.001, cutoff value=1.81 mg/L). A significant association with 6th month CFT 
decrease ≥ 25% was found for serum MCP1 (244.69±49.34 pg/ml vs 319.24±94.88 pg/ml, 
p=0.017) and serum VEGF (90.84±37.33 vs 58.28±25.19, p=0.027). The combined model of 
serum VEGF and LDL-cholesterol was found to be predictive of 6th month hard exsudate 
severity (p=0.001, r2=0.463)  
Conclusions: Increased levels of hsCRP and ICAM1 were found to be significant biomarkers for 
early reduced anatomic response to anti-VEGF treatment. Cases with higher serum levels of 
such factors had increased CFT values, despite treatment, suggesting inner blood-retinal 
barrier breakdown that is not adequately responsive to anti-VEGF monotherapy. 
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Introduction 
 
Diabetic macular edema (DME) is a major cause of visual impairment in industrialized 
countries due to increasing prevalence of Diabetes Mellitus1. Pivotal trials, revealed that 
monthly intravitreal injections of vascular endothelial growth factor (VEGF) inhibitors, allowed 
DME cases to achieve significant gains in VA2, 3, therefore such agents have become the gold 
standard treatment for DME. However, a significant percentage of patients won’t achieve a 
sustained response to anti-VEGF injections4, 5. Additionally, there is a wide variability in the 
frequency of injections and duration of treatment required to achieve clinical stability6, 7. 
Therefore, there is increased interest in finding significant predictors of clinical response. 
While the pathogenesis of DME is not fully understood, it is known that prolonged 
hyperglycemia leads to activation of pro-inflammatory cascades that in turn cause structural 
damage to the capillary endothelium8. The end result is capillary obliteration leading to retinal 
ischemia9 and inner blood-retina-barrier (iBRB) breakdown causing intraretinal fluid 
accumulation10. Indeed, the pioneering studies DCCT11 and UKPDS12 identified the importance 
of metabolic control in delaying DR. More recently, attention shifted to identifying the 
molecular agents underlying the pathogenesis of DR. It is now well known that VEGF plays a 
crucial role in retinal angiogenesis and vasopermeability13, 14. Additionally, there seems to be 
increasing evidence that insulin resistance occurring in DM2 is associated with a subclinical 
pro-inflammatory state identified by increased levels of C-reactive protein and Interleukin-6 
(IL6)15-17. In the case of diabetic eye disease, there is evidence of increased levels of VEGF, 
IL618, Intracellular Adhesion Molecule 1 (ICAM1)19 and Monocyte chemoattractant protein-1 
(MCP1)20 in the aqueous or vitreous of patients with advanced DR. Despite, the increasing 
evidence of pro-inflammatory activity occurring in DR, there is little research on how such 
biochemical factors can potentially interfere with macular response to current intravitreal 
treatments. Considering DME is a local manifestation of a complex systemic disease, it is 
possible that different metabolic and pro-inflammatory profiles portend different diabetic eye 
disease patterns. In this regard, we evaluated several systemic factors encompassing 
metabolic, renal, cardiovascular and inflammatory functions known to be associated with the 
pathogenesis of DM and/or DR, in order to study the possible associations with tomographic 
features of DME, and to assess their value as possible biomarkers for anatomic response to 
anti-VEGF treatment. 
 
Methods 
 
This was a prospective interventional study including cases diagnosed and treated for DME at 
the Ophthalmology Department of Hospital de Braga, Braga, Portugal. Study protocols were 
submitted to and approved by the Hospital Ethics Committee. The research procedures 
followed the tenets of the declaration of Helsinki and all patients provided written informed 
consent for the inclusion in the study. The recruited cases had Diabetes Mellitus type 2 (DM2) 
and nonproliferative diabetic retinopathy (NPDR) with central-involved diabetic macular 
edema (DME). All cases underwent complete ophthalmological examination and diagnosis was 
confirmed by fluorescein angiography and spectral-domain-optical coherence tomography (SD-
OCT). The severity of NPDR and foveal involvement was graded based on fluorescein 
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angiography findings, according to the international clinical diabetic retinopathy and diabetic 
macular edema disease severity scales21. The following inclusion criteria were considered:  
cases with DM2, NPDR and central DME with CFT > 330 µm and intraretinal cysts in the foveal 
area. The exclusion criteria included: history of any other vision impairing ocular disease, 
history of retinal laser treatment or intravitreous injection, as well as those previously 
submitted to vitreoretinal surgery were excluded. Regarding systemic history, the could be no 
record of cardiovascular events in the preceding year, no known history of chronic infectious, 
inflammatory or malignant disease, and no surgical procedures or hospital admissions of any 
kind in the preceding 6 months. 
All recruited cases underwent treatment with intravitreous bevacizumab (BVZ) 
injections (1.25 mg/0.05 cc) following the strategy of 3 monthly injections plus pro re nata 
treatment according to tomographic criteria, namely persistent central subfield thickness > 
330 µm, with identifiable intraretinal cystic lesions and / or subretinal fluid. 
Blood samples were taken at baseline to evaluate the following systemic markers: 
cardiovascular risk (high sensitivity C-reactive protein, serum homocysteine), renal dysfunction 
(blood urea nitrogen (BUN), serum creatinine), hypercholesterolemia (low-density lipoprotein 
(LDL), high-density lipoprotein (HDL) and total cholesterol (T.Chol)) and diabetic profile 
(glycated hemoglobin, blood glucose level). Additionally, for each case a blood sample was 
obtained and centrifuged at 1000G to isolate the serum fraction which was then immediately 
stored at -80ºC, for posterior dosing of the following pro-inflammatory cytokines: VEGF, 
sICAM-1, MCP-1 and TNF-α, by enzyme-linked immunosorbent assay (ELISA) using the specific 
ELISA kits, procured from Sigma-Aldrich®. All procedures were performed according to the 
manufacturer's protocol. Samples were diluted accordingly, to comply with the detection 
range of the relevant assay. Color intensities were determined using a microplate reader. 
Duplicate samples were used in all assays. The level of each factor in serum was within the 
detection range of the relevant assay. 
 SD-OCT images were obtained with the Spectralis OCT (Heidelberg Engineering, 
Heidelberg, Germany) using the following acquisition protocol: a 30º horizontal foveal scan 
resulting from the averaging of 100 frames, and a 20x20º macular square consisting of 25 
individual horizontal scans, resulting from the averaging of a minimum of 20 frames. The value 
obtained in the 1mm central ring of the macular thickness map was considered the central 
foveal thickness (CFT). In cases with bilateral DME, the eye with highest CFT was chosen for 
this study. 
The main outcome measures were: change from baseline in CFT (µm) and macular volume 
(mm3), obtaining a CFT < 330 µm, achieving a CFT decrease ≥ 25% or a CFT decrease < 10% of 
baseline CFT. Also, regarding OCT analysis, three of the authors (PB, JC, RS) blinded to clinical 
records, registered and/or graded the following qualitative findings in the 5 central scans: 
subretinal fluid, largest intraretinal cyst (IRC) height (Figure 1), disruption of the ellipsoid zone 
(EZ) and presence of hyperreflective spots (HRS). The presence of HRS was graded based on 
the most common tomographic patterns, according to the following criteria: Grade 1 – few 
small clearly spaced HRS; Grade 2 – larger rounded HRS clumped closer together, some could 
cause faint shadowing in the underlying retinal layers; Grade 3 – even larger rounded HRS 
forming plaque like hyperreflective lesions with significant shadowing of the underlying retinal 
layers (Figure 2). Disruption of the EZ band was classified as grade 0 if there was continuous 
reflectivity in the 5 central scans; grade 1 if minor disruption (≤200 µm) was present; and grade 
2 if at least one large (>200 µm) disruption of the EZ was found22.  
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The systemic blood/serum concentrations of measured metabolic and pro-inflammatory 
factors were assessed for predictive associations with the previously listed anatomic response 
parameters at the 3rd month and 6th month of follow-up. Such time points were chosen 
because they correspond respectively to the moment in which all cases had received the 
mandatory loading dose of BVZ (3rd month) and the moment at which persistent DME is 
considered to be poorly responding to anti-VEGF treatment (6th month)4, 23. All recorded results 
were subject to statistical analysis using the IBM SPSS Statistics software (SPSS version 23, IBM 
Corporation). Numerical values are expressed as mean±standard deviation. The study of 
possible interactions between variables was performed by Spearman 2-tailed correlations. 
Predictive associations were studied by ordinary least squares regression and bivariate logistic 
regression. The value of significant systemic factors as biomarkers was further studied by ROC 
curve analysis. Categorical variables were assessed using chi-square test and numerical 
variables were compared by Mann-Whitney-U or Kruskal Wallis tests. Statistical significance 
was considered for p < 0.05. 
 
Results 
 
The study included 30 consecutive patients diagnosed with DME requiring treatment with 
intravitreal anti-VEGF injections. Mean patient age was 66.76±9.36 years and mean duration of 
DM2 was 17.20±6.85 years. Thirteen patients were on insulin therapy for a mean of 7.23±6.91 
years. All cases had NPDR, classified as moderate in 17 cases and severe in 13 cases. There was 
a significant association between NPDR severity and serum VEGF level; cases with severe NPDR 
had higher circulating VEGF than those with moderate NPDR (92.25±37.70 vs 59.42±25.87 
pg/ml, p=0.014) (Table 1). The mean baseline CFT value was 519.63±119.26 µm, improving to 
401.53±167.40 µm at the 6th month (p<0.001) (Figure 3). The mean CFT change from baseline 
was -135.31±139.76 at the 3rd month and -113.50±131.11 at the 6th month. Mean macular 
volume followed a similar improvement profile (11.08±2.22 mm3 at baseline improving to 
9.83±2.00 mm3 at the 6th month, p<0.001). Between the 3rd and 6th month visit, 8 cases had an 
increase in CFT, but the difference did not reach statistical significance (p=0.089 for CFT and 
p=0.061 for MV). A favorable anatomic response (≥ 25% decrease in CFT) was found in 13 
cases (43.3%) at the 6th month. On the other end, a limited anatomic response (< 10% 
decrease in CFT) was found in 10 cases (33.3%) at the 6th month. Finally a CFT < 330 µm was 
verified in 10 cases at the 6th month (33.3%). Such results were obtained with a mean of 
4.82±0.56 intravitreal bevacizumab injections. 
 
Systemic factors and quantitative macular outcomes  
 
No significant associations were found between systemic factors and baseline CFT or MV. At 
the third month of follow-up significant associations were found between both baseline hsCRP 
(3.33±2.01 vs 1.39±1.15 mg/L, p=0.007) and ICAM1 (975.54±265.49 vs 727.07±336.09 pg/ml, 
p=0.012) with obtaining a CFT decrease < 10% (Table 2). Logistic regression revealed a 
predictive association between hsCRP and CFT decrease < 10% (p=0.014, R2=0.249, odds 
ratio=2.17, confidence interval 95%, 1.17-4.04) and such association was independent of DM 
related variables such as duration of disease, blood glucose level and HbA1c percentage. On 
the other end of the anatomic response spectrum, a lower serum MCP1 level was significantly 
associated with a CFT decrease ≥ 25% (242.42±48.96 vs 315.93±93.14, p=0.015). ROC curve 
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analysis indicated hsCRP and ICAM1 as significant biomarkers for 3rd month reduced anatomic 
response (area under the curve (AUC)=0.807, p=0.009, cutoff value=1,54 mg/L for a sensitivity 
of 78.0% and a specificity of 61.9% for hsCRP; AUC=0.788, p=0.014, cutoff value=900.08pg/ml 
for sensitivity of 78.0% and specificity of 85.7% for ICAM1). 
At the sixth month of follow-up (Table 3), significant Spearman correlations with 6th month CFT 
were found for hsCRP (p=0.02, 0.423) and MCP1 (p=0.024, r=0.440). Mean 6th month CFT 
change correlated with hsCRP (p=0.007, r=0.468), MCP1 (p=0.015, r=0.472) and VEGF 
(p=0.034, r= - 0.416). Further exploring these results, we verified a significant association 
between higher hsCRP level and obtaining a CFT decrease < 10% (3.36±1.65 mg/L vs 1.28±1.24 
mg/L, p<0.001). Such association was found to be predictive by logistic regression analysis 
(p=0.009, R2=0.312, odds ratio=2.59, confidence interval 95%, 1.26-5.28) and such result was 
again independent of DM related variables (DM duration, blood glucose level and HbA1c 
percentage). ROC curve analysis of hsCRP as a biomarker for 6th month reduced anatomic 
response, indicated an AUC of 0.903, p<0.001, and a value of 1.81 mg/L for a sensitivity of 90% 
and specificity of 85%. A significant association with 6th month CFT decrease ≥25% was found 
for lower serum MCP1 (244.69±49.34 pg/ml vs 319.24±94.88 pg/ml, p=0.017) and higher 
serum VEGF (90.84±37.33 vs 58.28±25.19, p=0.027). By logistic regression serum VEGF was 
predictive of a 6th month significant anatomic response (p=0.029, R2=0.219, odds ratio=1.035, 
CI95%, 1.00-1.06) and such association was independent from DM related variables. Finally, a 
significant association was found between obtaining a 6th month CFT < 330 µm and hsCRP 
(1.10±0.96 vs2.48±1.83 mg/L, p=0.021) and MCP1 (238.96±46.47 vs 318.47±91.81 pg/ml, 
p=0.004), the latter was found to be a negative predictor of such outcome (logistic regression, 
p=0.035, r2=0.305, odds ratio=0.97).  
 
Systemic factors and qualitative macular outcomes 
The mean baseline intraretinal cyst height was 350.04±144.00 µm, improving to 
221.68±211.80 µm at the 6th month (p=0.002). A significant correlation was found between 
hsCRP and 6th month IRC height (p=0.004, r=0.588). Regarding HRS severity, at presentation 14 
cases were classified as grade 3, while 7 cases had grade 1 small HRS. The classification of HRS 
improved significantly at the 6th month (p=0.008, Wilcoxon signed rank) with grade 3 HRS 
persisting in only 8 cases. Stepwise linear regression revealed that only VEGF was predictive of 
baseline HRS grade (p=0.002, r2=0.340, beta=0.583). Regarding 6th month HRS grade, the 
statistical model including LDL-cholesterol and serum VEGF level, was found to be the most 
significantly predictive (p=0.001, r2=0.463) (Table 4). Cases with improved HE severity at the 6th 
month were significantly younger (58.88 vs 67.23 years-old, p=0.019), but no significant 
association was found between systemic factor levels and improvement of HE severity.  
Subretinal fluid (SRF) was present at baseline in 10 cases. Cases with SRF had significantly 
higher serum homocysteine levels (16.58 vs 13.24 μmol/L, p=0.032). There was a significant 
improvement in SRF at the 6th month, persisting but with reduced vertical height in only 3 
cases (p=0.02, Wilcoxon signed-rank).    
Finally, grade 2 EZ disruption was found at baseline in 17 cases, while at the 6th month such 
defects persisted in 14 cases (p=0.096). No significant associations were found for baseline EZ 
disruption grade, but cases with persistent grade 2 EZ band disruption had significantly higher 
serum VEGF when comparing with cases with continuous EZ band (50.42±23.30 vs 
82.65±31.39, p=0.031).  
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Discussion 
 
Our results revealed that systemic inflammatory factors such as hsCRP, ICAM1 and MCP1 may 
have an important role in the identification of anti-VEGF nonresponders. In fact, higher hsCRP 
levels were consistently associated with more severe cystoid macular edema (higher 6th month 
CFT, lower CFT change and larger intraretinal cysts), both hsCRP and ICAM1 were associated 
with early reduced anatomic response (CFT change < 10%) and both hsCRP and MCP1 were 
significantly lower in cases which obtained a sixth month favorable anatomical outcome (CFT < 
330 µm). These results suggest a prominent role for pro-inflammatory factors causing 
persistent cystoid edema despite treatment with anti-VEGF. In this regard, it is interesting to 
note that hsCRP, an inflammatory protein associated with cellular apoptosis, was found by 
ROC curve analysis, to be a statistically significant biomarker of reduced foveal response to 
BVZ, particularly at the 6th month of follow-up when for suitable cases treatment was 
administered according to pro ne nata strategy, which resulted in a small increase in CFT in 8 
cases. Such result suggests that despite the anatomic response to the initial anti-VEGF loading 
dose, cases with higher hsCRP values, may benefit from a more prolonged monthly treatment 
dosing. Alternatively, considering the inhibitory effect of corticosteroids in leukocyte 
migration24, if OCT imaging reveals severe macular edema with large intraretinal cystic spaces 
after the loading dose of anti-VEGF, the patient could benefit from early switching to a 
corticosteroid implant. Such point is particularly important as it is well known that chronic 
cystoid macular edema may lead to permanent neuronal retinal damage thereby limiting the 
potential for visual acuity recovery25. It is therefore of the utmost importance to identify as 
early as possible those cases that exhibit limited anatomic response to anti-VEGF treatment in 
order to promptly optimize treatment strategies. A possible interpretation is that in cases with 
higher circulating pro-inflammatory proteins, the cystoid edema is probably more related to 
cellular iBRB breakdown rather than increased vasopermeability from hypoxia-induced VEGF 
expression. Indeed, leukostasis is considered to have a prominent role in the pathogenesis 
leading to iBRB breakdown, with upregulated ICAM1 playing a role in increased leukocyte 
adhesion to the capillary endothelium, while MCP1 seems to be an important biomarker for 
increased leukocyte mobilization to the retina26.  Previous studies had demonstrated a role for 
elevated CRP in DR and DME27-30, but to our knowledge, this is the first study identifying a 
relation between hsCRP level and macular outcomes in DME cases having completed a 
treatment course of at least 4 BVZ injections.  
Also of note was the finding of a significant correlation between systemic VEGF level and the 
stage of NPDR. Previous studies demonstrated a correlation between serum VEGF and 
occurrence of DR31-33 and DME34, but the results are not unanimous. In fact, a recent meta-
analysis reviewed the literature on circulating biomarkers of diabetic retinopathy and verified 
that VEGF was not consistently elevated comparing to diabetic patients without DR35. The 
previous referred studies did not provide detail on the composition of the NPDR group, also 
the immunoassay technique varied among studies, which adding to the inherent complexity of 
studying a systemic disease such as DM may at least partly explain the different reports. In 
order to minimize the effect of unrelated systemic conditions, we did not include any cases 
with any other known infectious, inflammatory or malignant disease, additionally we excluded 
all cases with hospital admissions due to cardiovascular events in the prior 12 months. Also, 
we included two biomarkers currently in use to assess cardiovascular risk (hsCRP and 
homocystein), which provided and objective indicator to guide the review of systemic history 
records. Nevertheless, experimental models reveal that VEGF expression increases in the 
hypoxic retina36. Considering VEGF is a mediator of angiogenesis37 it is theoretically feasible 
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that as RD progresses there is increased stimulus for retinal VEGF expression. Prolonged DM 
increases the risk of vascular damage affecting the eyes, kidneys and peripheral nerves and is 
also a major risk factor for acute ischemic events affecting the brain and the heart, we could 
therefore hypothesize that the correlation of serum VEGF to NPDR stage suggests either a 
tendency of ocular disease to mirror the overall systemic vascular state or that ocular 
expression of VEGF is reliably detected in the systemic circulation. In this regard, it is worth 
noticing that a significant association was found between higher serum VEGF levels and 
persistent photoreceptor EZ disruption. Such result suggests that in this study population the 
higher serum VEGF could indicate a more advanced hypoxic ocular state leading to impaired 
photoreceptor metabolism and decreased reflectivity of the EZ. Also of interest in our study 
was the relation of serum VEGF with hard exudate grade on OCT imaging. It is known that 
VEGF, a potent mediator of vascular permeability, is secreted by the retinal Muller cells under 
hypoxic conditions38, facilitating leakage of plasma protein and lipid into the retinal space. It is 
therefore possible that patients with higher VEGF levels may be more prone to pronounced 
exudation as the increased capillary permeability may supersede the capacity of the retinal 
pigment epithelium to remove the accumulating plasmatic molecules. In agreement with the 
ETDRS report39, we also found dyslipidemia to be an important factor for HRS severity, namely 
patients with higher LDL-cholesterol had significantly more severe HRS. In fact both VEGF and 
LDL- cholesterol were associated with HE severity after 6 months of treatment, meaning that 
while BVZ is effective at significantly reducing macular thickness, the complete reabsorption of 
lipoproteinaceous material may take much longer to occur if at all. Such results suggest that in 
patients with DME and pronounced hard exudates visible on fundoscopy, optimum control of 
blood lipids may be beneficial in order to mitigate the leakage of potentially inflammatory 
lipoproteins34, 40. 
 Finally, it is also important to notice that despite the importance of glycemic control in 
delaying the progress of DR, in this study glycemic variables (blood glucose level and HbA1c) 
had no correlation with either baseline or 6th month macular features. A previous study 
evaluated the role of metabolic factors on the clinical response to BVZ41. The authors verified 
that cases with better glycemic control (HbA1C <7%) had more significant improvements in 
central subfield thickness (CST), but there was no significant difference in final CST between 
groups. In this regard, a study by Bressler et al42 reviewed several systemic and ocular variables 
in cases with DME treated with ranibizumab, but after 1 year of follow-up, no significant 
difference in CST was found according to HbA1c value (<7.5% vs >7.5%). While glycemic 
control is a crucial factor in delaying the onset of clinical DR, glucose parameters may not be 
reliable markers for DME clinical response. In fact, glycated hemoglobin translates the mean 
plasmatic glucose concentration of the preceding 3 months, such value may rapidly change 
with dietary adjustment and oral antidiabetics or insulin treatment. Considering the risk of DR 
increases with duration of diabetes43, the most recent HbA1c value may not reflect the 
longstanding hyperglycemia that led to ocular disease. The largest studies evaluating the role 
of systemic factors on clinical response to DME treatment are the post hoc analysis of the 
RIDE/RISE trials44, 45. In such studies, no systemic variables were found to be correlated with 
macular outcomes, but components of systemic state such a cardiovascular status were based 
on medical records, and not on reliable laboratory markers, additionally no serum or ocular 
cytokines were studied, which limits the insight on the evaluation of inflammatory status in the 
pathogenesis of DME. Our study has limitations, namely the fact that the study population is 
small and systemic biomarkers where only measured at baseline. Nevertheless we believe our 
results are relevant as in addition to a rigorous effort to exclude possible confounding factors, 
we performed an extensive study of all major systemic variables related to DM by 
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quantification of corresponding biochemical factors, with particular emphasis on pro-
inflammatory status (hsCRP, VEGF, ICAM1, MCP1 and TNFα). Additionally, the results provided 
relevant insight regarding the possible effect of systemic inflammation in the pathogenesis of 
persistent DME and may lead to improvement of current clinical practices, namely in guiding 
implementation of DME treatment strategies according to inflammatory profiles. 
 
Conclusions 
 
In conclusion, our study revealed a significant effect of systemic inflammatory status 
on DME treatment, verified in a real-world practice setting.  Indeed, the levels of serum VEGF, 
LDL-cholesterol, MCP-1 and hsCRP revealed to be significantly associated with tomographic 
features of DME. More importantly, we verified that elevated systemic inflammatory factors 
such as hsCRP and MCP1, were associated with increased CFT, six months after commencing 
BVZ treatment, indicating a possible role for identification of anti-VEGF nonresponders. A 
longer follow-up and larger study population will be crucial to identifying the true role of such 
systemic biomarkers as prognostic factors for clinical response in DME, and eventually lead to 
the optimization of current treatment guidelines.  
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Tables 
 
Table 1 – demographic and laboratory data according to diabetic retinopathy type 
 Moderate NPDR Severe NPDR P value 
Age 63.00±10.09 66.71±17.52 0.476 
DM2 years 18.50±8.59 21.92±17.73 0.497 
Glucose 177.50±58.11 178.64±34.59 0.072 
HbA1c 8.10±1.07 7.80±1.08 0.660 
Creatinin 1.18±1.04 0.89±0.20 0.448 
B.U.N 38.81±14.95 53.21±17.16 0.019 
LDL 106.87±37.36 107.68±27.11 0.702 
HDL 48.60±12.05 53.71±21.25 0.790 
Total-Chol 184.18±51.52 185.92±25.33 0.111 
hsCRP 1.94±1.81 2.00±1.60 0.886 
Homocystein 13.91±3.46 15.07±4.71 0.257 
VEGF 59.42±25.87 92.25±37.70 0.027 
MCP1 308.71±102.86 272.27±33.77 0.164 
ICAM1 821.61±384.29 778.76±274.97 0.984 
TNFα 0.078±0.075 0.058±0.012 0.237 
 
 
Table 2 – Mean value of systemic factors and macular outcomes at the third month of 
follow-up 
Systemic 
factors 
CFT decrease < 
10% 
P 
Value 
CFT decrease ≥ 
25% 
P 
Value 
CFT < 330 µm P 
Value 
Yes No Yes No Yes No 
Glucose 184,60 174,75 0.321 189,16 170,61 0.152 177,77 178,14 0.705 
HbA1c % 8,51 7,79 0.921 8,02 7,92 0.310 8,17 7,87 0.395 
Creatinine 0,95 1,09 0.657 1,21 ,89 0.518 1,35 ,91 0.722 
B. U. N 53,66 44,04 0.328 44,00 46,55 0.545 44,00 46,19 0.563 
LDL-Chol 93,71 113,05 0.720 115,66 101,64 0.153 113,60 104,53 0.060 
HDL-Chol 48,62 52,00 0.625 48,50 52,64 0.884 50,33 51,26 0.790 
Total-Chol 162,11 194,80 0.235 191,66 180,55 0.207 192,00 182,00 0.226 
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Homocyst. 15,80 13,88 0.413 14,45 14,46 0.819 12,98 15,09 0.397 
hsCRP 3,33 1,39 0.007 1,55 2,25 0.368 1,60 2,13 0.372 
VEGF 60,66 77,97 0.188 82,44 66,62 0.281 74,01 72,94 0.868 
MCP1 347,71 261,66 0.094 242,42 315,93 0.015 266,57 294,50 0.597 
ICAM1 975,54 727,07 0.012 687,08 877,97 0.172 717,98 837,49 0.533 
TNFa 0.051 0.076 0.866 ,055 ,080 0.919 ,10 ,054 0.874 
 
 
Table 3 – Mean value of systemic factors and macular outcomes at the sixth month of 
follow-up 
Systemic 
factors 
CFT decrease < 
10% 
P 
Value 
CFT decrease ≥ 
25% 
P 
Value 
CFT < 330 µm P 
Value 
Yes No Yes No Yes No 
Glucose 184,60 174,75 0.350 182,92 174,29 0.711 178,63 177,68 0.933 
HbA1c % 8,51 7,79 0.053 7,78 8,10 0.385 7,86 8,02 0.641 
Creatinine 1,01 1,07 0.120 1,18 ,95 0.408 1,22 ,95 0.350 
B. U. N 54,90 40,85 0.120 38,23 51,12 0.059 36,45 46,79 0.062 
LDL-Chol 102,36 109,70 0.713 119,80 97,65 0.094 114,74 102,91 0.145 
HDL-Chol 58,80 47,08 0.131 48,15 53,15 0.805 51,45 50,71 0.420 
Total-Chol 187,60 183,70 0.713 198,15 174,94 0.300 194,18 179,68 0.268 
Homocyst. 16,41 13,48 0.074 13,15 15,45 0.103 13,02 15,29 0.094 
hsCRP 3,36 1,28 <0.001 1,44 2,38 0.072 1,10 2,48 0.021 
VEGF 53,95 80,44 0.094 90,84 58,28 0.027 77,61 70,16 0.646 
MCP1 291,33 282,44 0.427 244,69 319,24 0.017 238,96 318,47 0.004 
ICAM1 952,87 725,98 0.183 746,47 843,78 0.742 665,02 880,69 0.102 
TNFa 0.052 0.076 0.988 ,079 ,062 0.311 ,0942 ,052 0.919 
 
 
Table 4 – mean total cholesterol and serum VEGF levels according to hyperreflective (HRS) 
spots grade at the 6th month of follow-up 
 
 
6.Month HRS grade N Mean Std. Deviation Minimum Maximum p value 
Chol. 
Total 
1,00 9 169,11 40,15 99,00 228,00 
0.052 
2,00 13 182,53 33,16 131,00 240,00 
3,00 8 206,87 47,68 132,00 304,00 
Total 30 181,3000 40,73391 99,00 304,00 
VEGF 
1,00 7 45,57 17,51 23,94 78,70 
0.032 
2,00 12 75,63 35,97 20,91 153,41 
3,00 7 97,07 28,72 50,34 132,01 
Total 26 73,86 36,67764 3,94 153,41 
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Figure Legends 
 
Figure 1 
 
Intraretinal cyst height was measured using the caliper in the Heidelberg Eye Explorer software 
(HeyEX), by placing the cursor in the superior limit of the cyst hyporeflectivity and dragging 
along the shape of the cyst until the lower hyporreflective limit 
 
Figure 2 
 
The presence of hyperrreflective spots (HRS) corresponding to hard exsudates was classified 
according to severity in 3 grades. A – only a few, small, clearly spaced HRS are identifiable 
(grade 1); B - larger rounded HRS clumped closer together (grade 2); C - larger rounded HRS, 
some of which become coalescent forming  hyper reflective plaque-like deposits with 
significant shadowing effect of the underlying retinal layers (grade 3). 
 
Figure 3 
 
The boxplot graph represents the mean central foveal thickness during follow-up. The numeric 
values correspond to the the mean 50th percentile for CFT at each time point, indicating a 
significant change from baseline to the third month and a nonsignificant increase at the 6th 
month  
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